Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 129,688 | 164,859 | 114,449 | 81,732 | 74,787 |
| Cost of Goods | 2,554 | 1,585 | 1,521 | 4,679 | 2,553 |
| Gross Profit | 127,134 | 163,274 | 112,928 | 77,053 | 72,234 |
| Operating Expenses | 160,119 | 138,928 | 126,099 | 120,406 | 133,524 |
| Operating Income | -32,431 | 24,931 | -12,650 | -42,674 | -60,737 |
| Interest Expense | 2,294 | 2,751 | 2,846 | 2,857 | 2,817 |
| Other Income | 13,660 | 3,534 | 2,761 | 4,344 | 3,214 |
| Pre-tax Income | -21,065 | 25,714 | -12,735 | -41,187 | -60,340 |
| Income Tax | 921 | 8 | 20 | 39 | -72 |
| Net Income Continuous | -21,986 | 25,706 | -12,755 | -41,226 | -60,268 |
| Net Income Discontinuous | N/A | 0 | 0 | 0 | 4 |
| Net Income | $2,729 | $25,706 | $-12,755 | $-41,226 | $-60,264 |
| EPS Basic Total Ops | 0.03 | 0.29 | -0.14 | -0.47 | -0.71 |
| EPS Basic Continuous Ops | -0.25 | 0.29 | -0.14 | -0.47 | -0.70 |
| EPS Diluted Total Ops | 0.04 | 0.28 | -0.14 | -0.47 | -0.71 |
| EPS Diluted Continuous Ops | -0.21 | 0.25 | -0.14 | -0.47 | -0.70 |
| EPS Diluted Before Non-Recurring Items | 0.03 | 0.28 | -0.14 | -0.47 | -0.73 |
| EBITDA(a) | $-17,090 | $40,719 | $1,366 | $-29,872 | $-51,456 |